RT @ericdeinmd: Year in Review #ACR22 Pre-expos PPx for COVID! Tix-Cil (Evusheld): risk reduction 77% Cardiac AES 0.6% v

Year in Review #ACR22 Pre-expos PPx for COVID! Tix-Cil (Evusheld): risk reduction 77% Cardiac AES 0.6% vs placebo 0.2% Only 3.3% were on immunosuppression But Israeli study with immunosuppressed: 92% half as likely to be hospitalized or die 1/2 less infections @RheumNow